Semax official-source update · version 1
This page preserves this version’s findings and source pins. Open the current profile →
Official-source update
Reviewed 2026-09-19 · Preserved version 1
The 2026 assessment did not establish the nominated uses
FDA’s briefing found insufficient evidence for cerebral ischemia, migraine and trigeminal neuralgia. The reviewed clinical references had limited methods and outcome information; this is the agency’s scoped assessment. FDA PDF pp. 29 ↗
More findings and the sources behind them
Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.
Uncontrolled symptom reports have limited interpretability
For migraine and trigeminal neuralgia, FDA described small uncontrolled studies with unclear rating scales and incomplete reporting. Before-and-after changes alone cannot distinguish treatment effects from other explanations. FDA PDF pp. 26, 28 ↗
Nonclinical effects are not established clinical benefits
The briefing discusses neurological and other effects in rodents but poorly understood mechanisms and missing toxicology relevant to the proposed subcutaneous route. Those findings cannot be promoted into demonstrated human efficacy. FDA PDF pp. 37 ↗
Form and safety reporting remain important gaps
Clinical references often did not specify free base versus salt, and many did not discuss safety. FDA raised questions about bleeding and injectable-product immunogenicity; these are concerns requiring evidence, not quantified risks established by these reports. FDA PDF pp. 37, 41 ↗
What remains to be checked
- Check subsequent advisory records and any final FDA action separately from the staff briefing.
- Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage
PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.
FDA semax briefing for the July 2026 advisory meeting ↗
Source dated 2026-07-23; retrieved 2026-09-19.
- The 2026 assessment did not establish the nominated uses · PDF pp. 29 of 69
- Uncontrolled symptom reports have limited interpretability · PDF pp. 26, 28 of 69
- Nonclinical effects are not established clinical benefits · PDF pp. 37 of 69
- Form and safety reporting remain important gaps · PDF pp. 37, 41 of 69
SHA-256:
391f5586c1af1cf08d96d1a070c3800786e4e97b6eac069ff94e6fd2c5161599